Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (date from preprint)
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -3% Improvement Relative Risk Death/ICU -3% Famotidine  Shoaibi et al.  LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? Retrospective 28,636 patients in the USA No significant difference in outcomes seen c19early.org Shoaibi et al., American J. Gastroente.., Sep 2020 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021
 
*, now with p = 0.00026 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment.
risk of death, 3.0% higher, RR 1.03, p = 0.67, treatment 1,816, control 26,820.
risk of death/ICU, 3.0% higher, RR 1.03, p = 0.62, treatment 1,816, control 26,820.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, peer-reviewed, 5 authors.
This PaperFamotidineAll
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
PhD Azza Shoaibi, PharmD Stephen Fortin, MS Rachel Weinstein, Jesse A Berlin, PhD Patrick Ryan
doi:10.1101/2020.09.23.20199463
All authors contributed to the conceptualization and design of the study. SF authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors reviewed and contributed to the manuscript writing. .
References
Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Communications in statistics-simulation and computation
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life sciences
Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study, Gastroenterology
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology
Howden, Tytgat, The tolerability and safety profile of famotidine, Clinical therapeutics
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, J Biol Regul Homeost Agents
Malone, Tisdall, Smith, COVID-19: Famotidine, histamine, mast cells, and mechanisms
Mather, Seip, Mckay, Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, Official journal of the American College of Gastroenterology| ACG
Suchard, Schuemie, Krumholz, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, The Lancet
Walker, Patrick, Lauer, A tool for assessing the feasibility of comparative effectiveness research, Comp Eff Res
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B
{ 'indexed': {'date-parts': [[2022, 1, 19]], 'date-time': '2022-01-19T16:51:07Z', 'timestamp': 1642611067001}, 'reference-count': 19, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '4', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Am J Gastroenterol'], 'published-print': {'date-parts': [[2021, 4]]}, 'DOI': '10.14309/ajg.0000000000001153', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 21]], 'date-time': '2021-02-21T10:36:24Z', 'timestamp': 1613903784000}, 'page': '692-699', 'source': 'Crossref', 'is-referenced-by-count': 7, 'title': ['Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients'], 'prefix': '10.14309', 'volume': '116', 'author': [ {'given': 'Azza', 'family': 'Shoaibi', 'sequence': 'first', 'affiliation': []}, {'given': 'Stephen Patrick', 'family': 'Fortin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rachel', 'family': 'Weinstein', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jesse A.', 'family': 'Berlin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Ryan', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2021, 1, 28]]}, 'reference': [ { 'key': 'R1-20210511', 'first-page': 'rs', 'article-title': 'COVID-19: Famotidine, histamine, mast cells, and mechanisms', 'volume': 'rs.3', 'author': 'Malone', 'year': '2020', 'journal-title': 'Res Sq'}, { 'key': 'R2-20210511', 'doi-asserted-by': 'crossref', 'first-page': '36', 'DOI': '10.1016/S0149-2918(96)80177-9', 'article-title': 'The tolerability and safety profile of famotidine', 'volume': '18', 'author': 'Howden', 'year': '1996', 'journal-title': 'Clin Ther'}, { 'key': 'R3-20210511', 'first-page': '9', 'article-title': 'Mast cells contribute to coronavirus-induced inflammation: New ' 'anti-inflammatory strategy', 'volume': '34', 'author': 'Kritas', 'year': '2020', 'journal-title': 'J Biol Regul Homeost Agents'}, { 'key': 'R4-20210511', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'volume': '10', 'author': 'Wu', 'year': '2020', 'journal-title': 'Acta Pharmaceutica Sinica B'}, { 'key': 'R5-20210511', 'doi-asserted-by': 'crossref', 'first-page': 'PL365', 'DOI': '10.1016/S0024-3205(96)00553-X', 'article-title': 'The effect of histamine type 2 receptor antagonists on human ' 'immunodeficiency virus (HIV) replication: Identification of a new class ' 'of antiviral agents', 'volume': '59', 'author': 'Bourinbaiar', 'year': '1996', 'journal-title': 'Life Sci'}, { 'key': 'R6-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1129', 'DOI': '10.1053/j.gastro.2020.05.053', 'article-title': 'Famotidine use is associated with improved clinical outcomes in ' 'hospitalized COVID-19 patients: A propensity score matched ' 'retrospective cohort study', 'volume': '3', 'author': 'Freedberg', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'issue': '10', 'key': 'R7-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1617', 'DOI': '10.14309/ajg.0000000000000832', 'article-title': 'Impact of famotidine use on clinical outcomes of hospitalized patients ' 'with COVID-19', 'volume': '115', 'author': 'Mather', 'year': '2020', 'journal-title': 'J Am Coll Gastroenterol'}, { 'key': 'R8-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1592', 'DOI': '10.1136/gutjnl-2020-321852', 'article-title': 'Famotidine use and quantitative symptom tracking for COVID-19 in ' 'non-hospitalised patients: A case series', 'volume': '69', 'author': 'Janowitz', 'year': '2020', 'journal-title': 'Gut'}, { 'key': 'R9-20210511', 'article-title': 'Association between famotidine use and COVID-19 severity in Hong Kong: ' 'A territory-wide study', 'author': 'Cheung', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'key': 'R10-20210511', 'doi-asserted-by': 'crossref', 'first-page': '153', 'DOI': '10.4111/kju.2014.55.3.153', 'article-title': 'Nonmetastatic castration-resistant prostate cancer', 'volume': '55', 'author': 'Hong', 'year': '2014', 'journal-title': 'Korean J Urol'}, { 'key': 'R11-20210511', 'doi-asserted-by': 'crossref', 'first-page': 'S131', 'DOI': '10.1097/MLR.0b013e318070c08e', 'article-title': 'Increasing levels of restriction in pharmacoepidemiologic database ' 'studies of elderly and comparison with randomized trial results', 'volume': '45', 'author': 'Schneeweiss', 'year': '2007', 'journal-title': 'Med Care'}, { 'key': 'R12-20210511', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of hydroxychloroquine in hospitalized patients with COVID-19', 'volume': '383', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'R13-20210511', 'doi-asserted-by': 'crossref', 'first-page': '2005', 'DOI': '10.1093/ije/dyy120', 'article-title': 'Evaluating large-scale propensity score performance through real-world ' 'and synthetic data experiments', 'volume': '47', 'author': 'Tian', 'year': '2018', 'journal-title': 'Int J Epidemiol'}, { 'key': 'R14-20210511', 'first-page': '11', 'article-title': 'A tool for assessing the feasibility of comparative effectiveness ' 'research', 'volume': '2013', 'author': 'Walker', 'year': '2013', 'journal-title': 'Comp Eff Res'}, { 'key': 'R15-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1228', 'DOI': '10.1080/03610910902859574', 'article-title': 'Using the standardized difference to compare the prevalence of a binary ' 'variable between two groups in observational research', 'volume': '38', 'author': 'Austin', 'year': '2009', 'journal-title': 'Commun Stat Simul Comput'}, { 'issue': '1', 'key': 'R16-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1145/2414416.2414791', 'article-title': 'Massive parallelization of serial inference algorithms for a complex ' 'generalized linear model', 'volume': '23', 'author': 'Suchard', 'year': '2013', 'journal-title': 'ACM Trans Model Comput Simul'}, { 'key': 'R17-20210511', 'article-title': 'Famotidine use is not associated with 30-day mortality: A coarsened ' 'exact match study in 7158 hospitalized COVID-19 patients from a large ' 'healthcare system', 'author': 'Yeramaneni', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'key': 'R18-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1298', 'DOI': '10.1001/jama.2020.16761', 'article-title': 'Effect of hydrocortisone on 21-day mortality or respiratory support ' 'among critically ill patients with COVID-19: A randomized clinical ' 'trial', 'volume': '324', 'author': 'Dequin', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': 'R19-20210511', 'doi-asserted-by': 'crossref', 'first-page': '1307', 'DOI': '10.1001/jama.2020.17021', 'article-title': 'Effect of dexamethasone on days alive and ventilator-free in patients ' 'with moderate or severe acute respiratory distress syndrome and ' 'COVID-19: The CoDEX randomized clinical trial', 'volume': '324', 'author': 'Tomazini', 'year': '2020', 'journal-title': 'JAMA'}], 'container-title': ['American Journal of Gastroenterology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.14309/ajg.0000000000001153', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 5, 11]], 'date-time': '2021-05-11T19:57:13Z', 'timestamp': 1620763033000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1, 28]]}, 'references-count': 19, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021]]}}, 'URL': 'http://dx.doi.org/10.14309/ajg.0000000000001153', 'relation': {}, 'ISSN': ['0002-9270', '1572-0241'], 'issn-type': [{'value': '0002-9270', 'type': 'print'}, {'value': '1572-0241', 'type': 'electronic'}], 'subject': ['Gastroenterology', 'Hepatology'], 'published': {'date-parts': [[2021, 1, 28]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit